13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773195
Total reported value
$2.2B
$2.2B
92 檔
22.1%
According to the latest 13F quarterly dataset, Affinity Asset Advisors, LLC managed an equity portfolio of $2.2B at the end of Q4 2025, spanning 92 distinct U.S. exchange-listed positions.
Affinity Asset Advisors, LLC executed strategic sector rebalancing during Q4 2025, establishing 27 new positions while fully exiting 28 holdings and trimming 19 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 10.42% | — | — | |
| 2 | APGE | Apogee Therapeutics Inc | Stock-Other | 5.31% | +0.33% | +5.24% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 4.46% | -0.92% | -31.30% | |
| 4 | ABVX | Abivax Sa-adr | Stock-Other | 3.88% | -0.34% | +40.28% | |
| 5 | IBB | Ishares Biotechnology ETF | ETF-Tech | 3.85% | — | — | |
| 6 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 3.34% | — | +65.24% | |
| 7 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.19% | -0.68% | -10.71% | |
| 8 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.11% | -0.03% | — | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.90% | -0.26% | +128.57% | |
| 10 | AMGN | Amgen Inc | Stock-Healthcare | 2.70% | — | — | |
| 11 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.67% | +1.80% | +0.94% | |
| 12 | WVE | Wave Life Sciences Ltd. | Stock-Other | 2.62% | -0.52% | EXIT | |
| 13 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.49% | -1.61% | — | |
| 14 | XLV | Ss Health Care Select Sector | ETF-Other | 2.21% | — | — | |
| 15 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 2.10% | +1.99% | +112.50% | |
| 16 | ACLXGBX | Arcellx Inc | Stock-Other | 1.95% | -2.15% | EXIT | |
| 17 | NUVL | Nuvalent Inc-a | Stock-Other | 1.85% | -0.05% | -16.07% | |
| 18 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 1.81% | -0.28% | -17.32% | |
| 19 | ALKS | Alkermes plc | Stock-Healthcare | 1.59% | +0.79% | -20.00% | |
| 20 | FBRX | Forte Biosciences Inc | Stock-Other | 1.57% | -0.25% | — | |
| 21 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.53% | +0.29% | -23.21% | |
| 22 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.51% | -0.14% | -2.67% | |
| 23 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.39% | -0.58% | EXIT | |
| 24 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.39% | +1.27% | -16.35% | |
| 25 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.27% | -1.53% | EXIT | |
| 26 | ANAB | Anaptysbio Inc | Stock-Other | 1.23% | -0.17% | — | |
| 27 | QURE | uniQure N.V. | Stock-Other | 1.16% | +0.53% | +183.33% | |
| 28 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 1.14% | +0.15% | +632.37% | |
| 29 | OMER 9.5 06-15-29Bond | Omeros CORP | Bond | 1.10% | -0.13% | +18.10% | |
| 30 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.09% | +1.39% | +4.46% | |
| 31 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.05% | +0.29% | — | |
| 32 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.03% | +0.31% | +10.00% | |
| 33 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.03% | -0.52% | -72.93% | |
| 34 | SVRA | Savara Inc | Stock-Other | 0.96% | -0.01% | +86.48% | |
| 35 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.86% | +0.01% | — | |
| 36 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.86% | -2.87% | EXIT | |
| 37 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.83% | +0.28% | -35.48% | |
| 38 | ERAS | Erasca Inc | Stock-Other | 0.83% | -0.12% | -9.00% | |
| 39 | VERA | Vera Therapeutics Inc | Stock-Other | 0.72% | -0.04% | -17.58% | |
| 40 | COGT | Cogent Biosciences Inc | Stock-Other | 0.71% | -0.70% | — | |
| 41 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.66% | +0.01% | +169.81% | |
| 42 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.65% | +0.31% | -40.00% | |
| 43 | JBIO | Jade Biosciences Inc | Stock-Other | 0.63% | +0.38% | +994.59% | |
| 44 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | Bond | 0.57% | — | — | |
| 45 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.55% | -0.03% | — | |
| 46 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.54% | +0.36% | +16.67% | |
| 47 | ✓ | Zura Bio LTD | Stock-Other | 0.54% | -0.40% | +42.32% | |
| 48 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.50% | — | — | |
| 49 | STRO | Sutro Biopharma Inc | Stock-Other | 0.49% | +0.38% | — | |
| 50 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.45% | +1.12% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VTYXUSD | Ventyx Biosciences Inc | +2.3% | +65.24% | Add |
| 2 | WVE | Wave Life Sciences Ltd. | +1.3% | +28.57% | Add |
| 3 | APGE | Apogee Therapeutics Inc | +1.3% | +5.24% | Add |
| 4 | ABVX | Abivax Sa-adr | +1.2% | +40.28% | Add |
| 5 | CYTK | Cytokinetics Inc | +1.2% | +128.57% | Add |
| 6 | BBIO | Bridgebio Pharma Inc | +1.1% | +392.31% | Add |
| 7 | ROIV | Roivant Sciences Ltd. | +1.1% | +112.50% | Add |
| 8 | CGEM | Cullinan Therapeutics Inc | +1% | +632.37% | Add |
| 9 | OMER 9.5 06-15-29Bond | Omeros CORP | +0.7% | +18.10% | Add |
| 10 | SYRE | Spyre Therapeutics Inc | +0.6% | +0.94% | Add |
| 11 | JBIO | Jade Biosciences Inc | +0.6% | +994.59% | Add |
| 12 | SVRA | Savara Inc | +0.5% | +86.48% | Add |
| 13 | OVID | Ovid Therapeutics Inc | +0.4% | +169.81% | Add |
| 14 | KPTI | Karyopharm Therapeutics Inc | +0.3% | +464.45% | Add |
| 15 | ✓ | Engene Holdings Inc | +0.3% | +735.55% | Add |
| 16 | NRIX | Nurix Therapeutics Inc | +0.3% | — | Unchanged |
| 17 | MBX | Mbx Biosciences Inc | +0.2% | +51.52% | Add |
| 18 | TSHA | Taysha Gene Therapies Inc | +0.2% | +10.00% | Add |
| 19 | SGMT | Sagimet Biosciences Inc-a | +0.2% | +228.07% | Add |
| 20 | NXTC | Nextcure Inc | +0.1% | +28.88% | Add |
| 21 | CLYM | Climb Bio Inc | +0.1% | — | Unchanged |
| 22 | ✓ | Zura Bio LTD | +0.1% | +42.32% | Add |
| 23 | ABUS | Arbutus Biopharma CORP | +0.1% | +146.76% | Add |
| 24 | RVMD | Revolution Medicines Inc | 0% | — | Unchanged |
| 25 | TEVA | Teva Pharmaceutical-sp Adr | 0% | — | Unchanged |
| 26 | ERAS | Erasca Inc | 0% | -9.00% | Trim |
| 27 | CELC 2.75 08-01-31Bond | Celcuity Inc | 0% | — | Unchanged |
| 28 | QTTB | Q32 Bio Inc | 0% | — | Unchanged |
| 29 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | Unchanged |
| 30 | ADGM | Adagio Medical Holdings Inc | 0% | — | Unchanged |
| 31 | AVTX | Avalo Therapeutics Inc | 0% | +4.46% | Add |
| 32 | OBIO | Orchestra Biomed Holdings In | 0% | -21.24% | Trim |
| 33 | EPRX | Eupraxia Pharmaceuticals Inc | 0% | — | Unchanged |
| 34 | CMPS | Compass Pathways PLC | 0% | — | Unchanged |
| 35 | VRDN | Viridian Therapeutics Inc | 0% | — | Unchanged |
| 36 | AVR | Anteris Technologies Global | 0% | +8.15% | Add |
| 37 | CATX | Perspective Therapeutics Inc | 0% | — | Unchanged |
| 38 | VERA | Vera Therapeutics Inc | -0.1% | -17.58% | Trim |
| 39 | ✓ | Newamsterdam Pharma Company | -0.1% | — | Unchanged |
| 40 | CRNX | Crinetics Pharmaceuticals In | -0.1% | — | Unchanged |
| 41 | GERN | Geron CORP | -0.1% | — | Unchanged |
| 42 | ✓ | -0.1% | — | Unchanged | |
| 43 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | -0.1% | — | Unchanged |
| 44 | NAMS | NewAmsterdam Pharma Company N.V. | -0.1% | — | Unchanged |
| 45 | IMVT | Immunovant Inc | -0.1% | -33.33% | Trim |
| 46 | CLDX | Celldex Therapeutics Inc | -0.1% | +16.67% | Add |
| 47 | ORKA | Oruka Therapeutics Inc | -0.2% | -16.35% | Trim |
| 48 | ✓ | Establishment Labs Holdings In | -0.3% | -35.48% | Trim |
| 49 | SMMT | Summit Therapeutics Inc | -0.3% | — | Unchanged |
| 50 | ✓ | -0.3% | -85.71% | Trim |
According to official SEC Form 13F filings, Affinity Asset Advisors, LLC reported a total U.S. public equity portfolio value of $2.2B across 92 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, APGE, INSM) accounted for 22.1% of total reported equity market value during Q4 2025.
Top New Position Initiated
XBI
市值: $182.9M
Top Position Liquidated / Trimmed
VRNA
前期市值: $66.7M
During Q4 2025, Affinity Asset Advisors, LLC's top holdings by market value included XBI (10.4%)、APGE (5.3%)、INSM (4.5%). The largest single position, XBI, represented 10.4% of total portfolio value.
In Q4 2025, Affinity Asset Advisors, LLC made 101 total portfolio adjustments, initiating 27 new buys, adding to 27 positions, trimming 19 holdings, and fully liquidating 28 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.